An Adaptive Approach to Drug Development

Reata’s mission is to develop novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in how cells produce energy and regulate inflammation. Our two most advanced clinical candidates (bardoxolone methyl and omaveloxolone) target important transcription factors, called Nrf2 and NF-κB, to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.